Notice: This company has been marked as potentially delisted and may not be actively trading. Range Cancer Therapeutics ETF (CNCR) Holdings Add Compare Share Share Holdings Stock AnalysisHeadlinesHoldingsRatingsShort InterestTrends Top 50 CNCR HoldingsRankCompanyCurrent PriceWeightShares Held1DNAGinkgo Bioworks$10.86-5.0%3.75%25,2632RXRXRecursion Pharmaceuticals$9.28-10.3%3.72%47,7073CMPXCompass Therapeutics$2.92-5.2%3.36%92,0384PGENPrecigen$1.91-3.0%2.79%157,4165GNLXGenelux$4.84+0.4%2.76%61,9636VORVor Biopharma$1.37-2.1%2.29%155,8277REPLReplimune Group$13.98-2.3%2.19%15,0478SDGRSchrödinger$22.64-5.7%2.12%7,9259BPMCBlueprint Medicines$92.25-2.2%2.00%1,82410EXELExelixis$36.85+5.0%2.00%5,730 Get the Latest News and Ratings for CNCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. 11GLUEMonte Rosa Therapeutics$6.22-6.2%1.97%28,00512BMYBristol-Myers Squibb$55.85+0.1%1.87%3,14913ZYMEZymeworks$14.39+2.6%1.87%12,58114SWTXSpringWorks Therapeutics$58.29-2.7%1.86%4,42615ELVNEnliven Therapeutics$21.80+1.5%1.61%7,03316IBRXImmunityBio$3.42-6.0%1.58%45,09717BNTXBioNTech$120.01+1.8%1.56%1,27518RVMDRevolution Medicines$41.34-2.2%1.55%3,53419IMCRImmunocore$29.92+0.2%1.49%4,77020DAWNDay One Biopharmaceuticals$12.43+1.6%1.45%11,54721ACLXArcellx$63.75-2.8%1.43%2,04522SNDXSyndax Pharmaceuticals$16.38+2.4%1.40%8,64823IPHAInnate Pharma$2.24-0.9%1.39%72,69524KPTIKaryopharm Therapeutics$0.60-1.9%1.35%205,62425MRUSMerus$47.37-0.5%1.35%3,13626XNCRXencor$15.74-0.3%1.32%7,44227HCMHUTCHMED$16.11+5.1%1.31%9,52228JANXJanux Therapeutics$36.01-3.1%1.29%3,15529AURAAura Biosciences$7.51-1.6%1.28%15,78730NUVBNuvation Bio$2.21-2.9%1.27%51,26631KYMRKymera Therapeutics$36.81-1.6%1.26%3,24732NUVLNuvalent$79.49-3.5%1.25%1,40433MGNXMacroGenics$2.76-4.2%1.24%45,88534RCUSArcus Biosciences$11.06+3.0%1.22%9,31335ARVNArvinas$17.77-3.3%1.22%6,25936NRIXNurix Therapeutics$16.87-1.0%1.22%6,18737MRKMerck & Co., Inc.$89.40+2.0%1.21%1,33538ACRVAcrivon Therapeutics$5.54-5.3%1.20%19,12439INBXInhibrx$12.56-1.9%1.19%9,03040GMABGenmab A/S$22.34-0.4%1.17%5,921Shocking Elon Move: Bigger than DOGE? (Ad)After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.Click here to see the details BEFORE March 17th…41LEGNLegend Biotech$39.70+2.0%1.13%3,06942SMMTSummit Therapeutics$22.12-4.1%1.12%5,34043GERNGeron$2.58-2.1%1.10%36,01544CRBUCaribou Biosciences$1.31-7.1%1.09%77,53045IMRXImmuneering$1.81+5.6%1.09%54,83846ACETAdicet Bio$0.97-2.7%1.06%104,92447ITOSiTeos Therapeutics$7.41-0.9%1.03%13,00848TYRATyra Biosciences$13.17+3.1%1.03%7,81149IDYAIDEAYA Biosciences$21.75+0.1%1.02%4,27450REGNRegeneron Pharmaceuticals$700.33+0.6%1.01%137 Geographic ExposureUnited States95.4%Netherlands2.1%Currency ExposureUSD100.0%Sector ExposureHealth Care27.6%Industry ExposureBiotechnology27.6%SubIndustry ExposureBiotechnology21.0%Pharmaceuticals2.4%Coupon Exposure4-60.6%Maturity Exposure5-100.6% Related Companies and Tools Related Companies JPMorgan Healthcare Leaders ETF Portfolio First Trust Nasdaq Pharmaceuticals ETF Portfolio ProShares UltraShort Nasdaq Biotechnology Portfolio Horizon Kinetics Medical ETF Portfolio Invesco Nasdaq Biotechnology ETF Portfolio F/m Emerald Life Sciences Innovation ETF Portfolio ProShares Ultra Nasdaq Biotechnology Portfolio Invesco Dorsey Wright Healthcare Momentum ETF Portfolio Invesco S&P SmallCap Health Care ETF Portfolio VanEck Biotech ETF Portfolio This page (NASDAQ:CNCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
